A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

Recruiting

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

Trial locations(305 sites)

United States

Research Site, Birmingham, Alabama

Research Site, Phoenix, Arizona

Research Site, Prescott Valley, Arizona

Research Site, Springdale, Arkansas

Research Site, Fountain Valley, California